EUVIMEDEUVIMED entdecken
Crossref

Integrating crystal engineering with PEG6000 conjugation to formulate advanced solid dispersions of febuxostat for gout management

Doriana T Ungur iD, Laura Patras iD, Mihaela M Pop iD, Coca A Iordache, Tudor L Tămaş iD, Alice Mija iD, Manuela Banciu iD

Journal of Pharmacy and Pharmacology · 05.03.2026 · 78 (3)

DOI: 10.1093/jpp/rgag019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 27.03.2026. Verfasst von Doriana T Ungur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biology and Geology, Doctoral School in Integrative Biology, Babeş-Bolyai University, 5-7 Clinicilor Street, Cluj-Napoca 400006, Romania. Hauptthemen laut MEDLINE: Febuxostat, Polyethylene Glycols, Gout Suppressants, Gout. Die Arbeit nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Febuxostat (FEB) is a poorly soluble xanthine oxidase inhibitor, which limits its in vitro dissolution performance. This study aimed to enhance the aqueous solubility and dissolution behavior of FEB through crystal engineering (salt and co-crystal formation) and the development of PEG6000-based amorphous solid dispersions.

Methods

Three FEB salts with p-toluenesulfonic acid (Tos1), tromethamine, and N-methyl-D-glucamine, as well as one FEB co-crystal with acridine (Acd1), were prepared together with their amorphous solid dispersions using PEG6000. Solubility, dissolution, and physical stability were evaluated in water and biorelevant media (FaSSIF). Cytotoxicity was assessed in HepG2 cells, while antioxidant and anti-inflammatory activities were investigated in monosodium urate–stimulated macrophages. Key findings Salt formation significantly improved FEB solubility, with Tos1 increasing solubility from 27 ± 2 μg/ml (FEB) to 100 ± 2 μg/ml in water and from 316 ± 2 μg/ml to 364 ± 2 μg/ml in FaSSIF. Incorporation into PEG6000 further enhanced Tos1 solubility to 134 ± 2 μg/ml in water and 481 ± 2 μg/ml in FaSSIF. In contrast, the Acd1 co-crystal showed limited solubility in water but exhibited slower dissolution, suggesting suitability for sustained-release applications. None of the novel formulations increased cytotoxicity. Tos1 and its PEG6000 dispersion maintained the highest HepG2 cell viability and significantly reduced malondialdehyde levels and intracellular uric acid in macrophages.

Conclusions

The combined application of crystal engineering and PEG6000-based amorphous solid dispersions selectively enhances the solubility, dissolution, and in vitro biological performance of febuxostat. This strategy offers a rational approach for optimizing FEB formulations and addressing the limitations associated with poorly soluble drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FebuxostatPolyethylene GlycolsGout SuppressantsGoutHumansSolubilityCrystallizationHep G2 CellsAnimalsAntioxidantsMacrophagesChemistry, PharmaceuticalCell SurvivalDrug CompoundingAnti-Inflammatory Agents

Stichwörter der Autor:innen

amorphous solid dispersionsfebuxostathyperuricemiaoxidative stresssolubility

Substanzen

FebuxostatPolyethylene GlycolsGout SuppressantsAntioxidantsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Faculty of Biology and Geology, Doctoral School in Integrative Biology, Babeş-Bolyai University, 5-7 Clinicilor Street, Cluj-Napoca 400006, Romania.
  • TeraCrystal SRL, 67-103 Donat Street, Cluj-Napoca 400293, Romania.
  • Department of Molecular Biology and Biotechnology, and Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, Babeş-Bolyai University, 5-7 Clinicilor Street, Cluj-Napoca 400006, Romani…
  • Department of Geology, Faculty of Biology and Geology, Babeş-Bolyai University, 1 Kogălniceanu Street, Cluj-Napoca 400084, Romania.
  • University Côte d'Azur, Institute of Chemistry of Nice, UMR CNRS 7272, 06108 Nice, France.

ORCID-Profile: Doriana T Ungur, Laura Patras, Mihaela M Pop, Tudor L Tămaş, Alice Mija, Manuela Banciu

Zitieren

APA

Ungur, D. T., Patras, L., Pop, M. M., Iordache, C. A., Tămaş, T. L., Mija, A., & Banciu, M. (2026). Integrating crystal engineering with PEG6000 conjugation to formulate advanced solid dispersions of febuxostat for gout management. Journal of Pharmacy and Pharmacology, 78(3). https://doi.org/10.1093/jpp/rgag019

Vancouver

Ungur DT, Patras L, Pop MM, Iordache CA, Tămaş TL, Mija A, et al. Integrating crystal engineering with PEG6000 conjugation to formulate advanced solid dispersions of febuxostat for gout management. Journal of Pharmacy and Pharmacology. 2026;78(3). doi:10.1093/jpp/rgag019

BibTeX
@article{Ungur2026,
  author = {Ungur, Doriana T and Patras, Laura and Pop, Mihaela M and Iordache, Coca A and Tămaş, Tudor L and Mija, Alice and Banciu, Manuela},
  title = {Integrating crystal engineering with PEG6000 conjugation to formulate advanced solid dispersions of febuxostat for gout management},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  volume = {78},
  number = {3},
  doi = {10.1093/jpp/rgag019}
}
Kostenlos starten →